Nevro, which is awaiting approval for an implanted electrical device that treats leg and back pain, raised $126 million by offering 7.0 million shares (vs. 6.25 million originally planned) at $18, above the $15 to $17 range. Nevro will list on the NYSE under the symbol NVRO. J.P. Morgan and Morgan Stanley acted as joint bookrunners on the deal.
